A novel rapamycin analog is highly selective for mTORC1 in vivo
Rapamycin extends lifespan in model organisms by targeting mTORC1, but exerts off-target side effects via inhibition of mTORC2. Here, the authors report the identification of a selective mTORC1 inhibitor, and show that it inhibits mTORC1 activity both in vitro and in vivo, with reduced side effects...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2019-07-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-11174-0 |